FT011 | Future&Tech

R&D

You can scroll left and right to view the full content.

Pipeline	Development Projects	Target diseases
FT005	FT005-002 (Hulk)	Chronic kidney disease
		Sarcopenia (muscle atrophy with aging)
		Muscular dystrophy
FT006	FT006-001 (Batman)	COVID prevention
FT007	FT005-002 (Hulk)	Cancer cachexia
FT007	FT005-007 (Steve)	Cancer cachexia
FT009	FT005-002 (Hulk)	Type 2 diabetes
FT011	FT005-005 (Paul)	Melanoma (skin cancer)
FT012	FT005-004 (Kyte)	Melanoma (skin cancer)

FT005-005 (Paul) project (target antigen: B7-H3 (CD276))

Various therapeutic strategies targeting B7-H3 (CD276)

Market size

Several B7-H3 targeted monoclonal antibodies are under clinical development for the treatment of prostate cancer
- MacroGenics: vobramitamab duocarmazine (vobra duo, MGC018), B7-H3 targeted antibody-therapeutic conjugate
- Daiichi Sankyoand Merk: ifinatamab deruxtecan (I-DXd), Target antibody-therapeutic conjugate
Currently, there are no specific market size data available for B7-H3 targeted monoclonal antibodies for treatment of prostate cancer. However, the overall market for B7-H3 inhibitors are expected to grow significantly in the following years. Based on ongoing clinical trials, the therapy is expected to hold great market potential once approved and commercialized.
According to a report published by DelveInsight, the market for B7-H3 inhibitors is exptected to grow at a CAGR of 7.5%-8.5%, backed by increased investments by major pharmaceutical companies and an increase in the number of clinical trials.
The total market size for metastatic castration-resistant prostate cancer (mCRPC) in seven major countries, including the US, is estimated at around USD 7 billion as of 2023.